Role of beta-adrenergic receptor blocking agents in hypertensive diseases: personal thoughts as the controversy persists (Q37629384)

21 August 2017

1 reference

title

Role of beta-adrenergic receptor blocking agents in hypertensive diseases: personal thoughts as the controversy persists (English)

1 reference

21 August 2017

1

Edward D Frohlich

1 reference

21 August 2017

publication date

6 November 2009

1 reference

Therapeutic advances in cardiovascular disease

21 August 2017

published in

1 reference

21 August 2017

volume

3

1 reference

21 August 2017

issue

6

1 reference

21 August 2017

page(s)

455-464

1 reference

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Cardiovascular protection using beta-blockers: a critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Beta-blockers for hypertension: time to call a halt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Atenolol in hypertension: is it a wise choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Beta-blockers and diabetes: the bad guys come good

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Beta blockers for the treatment of primary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Are we misunderstanding beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Mitral valve prolapse and borderline hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

A comparison of atenolol and nebivolol in isolated systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Hemodynamic, reflexive, and metabolic alterations induced by acute and chronic timolol therapy in hypertensive man

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Hemodynamic effects of intravenous labetalol in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Mechanism of the altered blood pressure responsiveness produced by chlorothiazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Current challenges and unresolved problems in hypertensive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Hemodynamic effects of celiprolol in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Dysglycemia and cardiovascular risk in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Nebivolol decreases endothelial cell stiffness via the estrogen receptor beta: a nano-imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Incident diabetes in clinical trials of antihypertensive drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

A comparison of timolol and propranolol in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

New-onset diabetes and antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

β-blockers in hypertension—the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Hemoglobin A1c poised to become preferred test for diagnosing diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Old antihypertensives and new diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

The latest generation of beta-blockers: new pharmacologic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

HYPOTENSIVE ACTION OF PRONETHALOL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

Are β-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709346519

21 January 2018

Identifiers

DOI

10.1177/1753944709346519

1 reference

21 August 2017

1 reference